famous cryptocurrency Related searches

Shenzhen Stock Exchange: The Shenzhen Stock Exchange, together with the Financial Office of Henan Provincial Party Committee, Henan Securities Regulatory Bureau and Zhengzhou Municipal Party Committee and Municipal Government, jointly held an industrial exchange meeting on "Shenzhen M&A Revitalizing Quality". This activity focused on the advantageous industries of high-end equipment manufacturing in Henan Province, discussed in depth the development characteristics of the industry and the main points of M&A investment, built an exchange platform, conveyed the concept of supervision, supported the integration of upstream and downstream of the industrial chain, strictly prevented insider trading in M&A and reorganization, and helped Henan develop new quality productivity according to local conditions. Next, Shenzhen Stock Exchange will continue to implement the requirements of "Six Articles on M&A" in accordance with the unified deployment of China Securities Regulatory Commission, adhere to the direction of marketization, adhere to the major strategy of serving the country, give full play to the role of the capital market as the main channel in enterprise M&A and reorganization, take various measures to support listed companies to standardize M&A and reorganization, promote the landing of high-quality cases, strengthen exchanges with market players, and strive to create a healthy and orderly market ecology.JPMorgan Chase: The target price of Netflix was raised from $850 to $1,010, and the "overweight" rating was maintained.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)

Baiyun Airport: The passenger throughput in the first November increased by 21.16% year-on-year. Baiyun Airport (600004) released the November production and operation data express on the evening of December 13th, and Baiyun Airport took 43,637 flights (sorties) in November, up by 12.94% year-on-year. Passenger throughput was 6,504,400 person-times, up by 19.94% year-on-year; The cargo and mail throughput was 212,100 tons, a year-on-year increase of 5.68%. Baiyun Airport took off and landed 465,983 sorties from January to November, up 12.05% year-on-year; The passenger throughput was 69.6674 million person-times, up by 21.16% year-on-year; The cargo and mail throughput was 2,161,300 tons, up 18.12% year-on-year.Shengyi Technology: The total sales volume of the company's rigid copper clad laminate ranks second in the world. Shengyi Technology said at the collective exchange meeting of investors that according to the statistics and ranking of the global rigid copper clad laminate in 2023 by Prismark of the United States, the total sales volume of the company's rigid copper clad laminate ranks second in the world, with a global market share of 14%. Regarding the growth trend of AI server, the company said that the upgrade iteration of hardware equipment related to AI server is fast, and the product form is quite different from that of previous wired products. The company can quickly respond to customer requirements and provide solutions. It is expected that AI applications will gradually develop from large model training to application in the future, and it is expected to achieve good growth.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.

Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)